American Century Companies Inc. Boosts Holdings in Genomic Health, Inc. (GHDX)

American Century Companies Inc. raised its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 0.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,294 shares of the medical research company’s stock after buying an additional 1,092 shares during the period. American Century Companies Inc. owned approximately 0.37% of Genomic Health worth $4,143,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dubuque Bank & Trust Co. increased its holdings in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after buying an additional 2,038 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after buying an additional 1,679 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Genomic Health in the first quarter valued at $218,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after buying an additional 993 shares in the last quarter. 88.91% of the stock is currently owned by institutional investors.

Shares of Genomic Health, Inc. (NASDAQ GHDX) opened at 31.88 on Monday. Genomic Health, Inc. has a 52 week low of $26.37 and a 52 week high of $33.97. The firm’s market capitalization is $1.10 billion. The firm’s 50-day moving average is $31.08 and its 200 day moving average is $31.53.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. During the same quarter in the previous year, the business earned ($0.18) earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. Equities research analysts forecast that Genomic Health, Inc. will post ($0.01) EPS for the current fiscal year.

GHDX has been the topic of several recent analyst reports. Canaccord Genuity cut their target price on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 15th. Jefferies Group LLC reissued a “hold” rating and set a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. Cowen and Company reissued a “hold” rating and set a $34.00 target price on shares of Genomic Health in a research note on Friday, September 1st. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $31.00 target price on shares of Genomic Health in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $32.00.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/09/11/american-century-companies-inc-boosts-holdings-in-genomic-health-inc-ghdx.html.

In related news, insider Phillip G. Febbo sold 3,174 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kimberly J. Popovits sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $32.59, for a total transaction of $162,950.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,642 shares of company stock valued at $1,195,131. 46.20% of the stock is owned by insiders.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply